Why the study?
Point-of-care platforms historically lacked the analytical precision of laboratory-based high-sensitivity troponin assays, limiting their use in accelerated assessment strategies for suspected acute coronary syndrome.
Does point-of-care high-sensitivity cardiac troponin testing improve the efficiency of assessment in patients with suspected acute coronary syndrome?
Does point-of-care high-sensitivity cardiac troponin testing improve the efficiency of assessment in patients with suspected acute coronary syndrome?
High-sensitivity point-of-care troponin assays offer the opportunity to rapidly and accurately assess patients with suspected acute coronary syndrome, matching the precision of laboratory-based tests.
Answers are grounded in this paper and cite their sources.
May expedite ED workflows for suspected ACS; leaves open need for prospective outcome validation versus laboratory assays.
Methods to improve the safety, accuracy and efficiency of assessment of patients with suspected acute coronary symptoms have occupied decades of study and have supported significant changes in clinical practice. Much of the progress is reliant on results of laboratory-based high-sensitivity cardiac troponin assays that can detect low concentrations with high precision. Until recently, point-of-care (POC) platforms were unable to perform with similar analytical precision as laboratory-based assays, and recommendations for their use in accelerated assessment strategies for patients with suspected acute coronary syndrome has been limited. As POC assays can provide troponin results within 20 min, and can be used proximate to patient care, improvements in the efficiency of assessment of patients with suspected acute coronary syndrome is possible, particularly with new high-sensitivity assays.
No takes yet. Share an insight, caveat, or question.
Cullen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: